SCHEMBL10127604

SCHEMBL10127604

COCCOc1cc([N+](=O)[O-])ccc1N1CCC(N2CCN(C)CC2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.45
POLB P06746 1/20 0.43
KMT2A Q03164 1/20 0.43
MAPT P10636 2/20 0.43
WDR5 P61964 5/20 0.43
KDM4E B2RXH2 1/20 0.42
LMNA P02545 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPK1 P28482 1/20 0.42
FGFR3 P22607 3/20 0.41
DRD2 P14416 1/20 0.41
ADRA1D P25100 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41
GAA P10253 2/20 0.41
HTT P42858 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10036124 0.91 MAPT (0.43) ALDH1A1POLBKMT2AMAPTWDR5
SCHEMBL10036381 0.90 ALDH1A1 (0.43) ALDH1A1POLBKMT2AMAPTWDR5
SCHEMBL10036382 0.90 WDR5 (0.43) ALDH1A1POLBKMT2AMAPTWDR5
SCHEMBL2904916 0.89 ALDH1A1 (0.51) ALDH1A1POLBKMT2AMAPTWDR5
SCHEMBL27038673 0.89 ALDH1A1 (0.43) ALDH1A1POLBKMT2AMAPTWDR5
SCHEMBL10036430 0.89 FGFR3 (0.47) ALDH1A1POLBKMT2AMAPTWDR5
SCHEMBL10036127 0.88 CHRNB2 (0.42) ALDH1A1POLBKMT2AMAPTWDR5
SCHEMBL10036436 0.87 ALDH1A1 (0.52) ALDH1A1MAPTWDR5KDM4ELMNA
SCHEMBL30306155 0.87 ALDH1A1 (0.52) ALDH1A1MAPTWDR5KDM4ELMNA
SCHEMBL16305338 0.83 ALDH1A1 (0.55) ALDH1A1POLBKMT2AMAPTWDR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ALDH1A1 1554/4885POLB 4590/4885KMT2A 103/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ALDH1A1 1554/4885POLB 4590/4885KMT2A 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.